БЛОГ

Mar 4, 2022

AgeX Therapeutics: Targeting Biological Ageing | Dr Michael D. West

Posted by in categories: biotech/medical, law, life extension

Have not heard from Dr West in awhile. Two things stood out in this technical hour: Telomerase in gene therapy has never been properly developed, and their iTR technology has not had animal trials as they wait for funding.


In this #webinar, Dr Michael West, a bioentrepreneur and CEO of AgeX Therapeutics, discussed the work of AgeX Therapeutics, their mission and plan to extend human health and longevity, and exciting new #technologies that could combat #ageing and unlock cellular immortality.

Register for upcoming #HealthyLongevity #webinar sessions at https://nus-sg.zoom.us/webinar/register/3016397215018/WN__sypkX6ZSomc7cGAkK3LbA
#NUSMedicine #webinarseries

References:
- Closing video source: https://www.youtube.com/watch?v=yoJ6LRCkNb0

Disclaimer: The opinions and advice expressed in this webinar are those of the speakers and do not represent the views and opinions of the organizers and National University of Singapore or any of its subsidiaries or affiliates. The information provided in this webinar is for general information purposes only as part of a general discussion on public health. The information is not intended to be a substitute for professional medical advice, diagnoses or treatment; and cannot be relied on in place of consultation with your licensed healthcare provider.

All Rights Reserved.
All of the proceedings of this webinar, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved to the speaker or NUS. No statement or presentation made is to be regarded as dedicated to the public domain. Any sound reproduction, transcript or other use of the material presented at this course without the permission of the speaker or NUS is prohibited to the full extent of common-law copyright in such material.

Leave a reply